Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label amlitelimab study in moderate to severe atopic dermatitis
2022-502188-39-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Sep 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 24
01
Overview
Phase 2, open-label, single-arm trial of amlitelimab in atopic dermatitis (AD), sponsored by Sanofi. Primary endpoints: Percentage of participants who experienced Treatment-Emergent Adverse Events and Percentage of participants who experienced Treatment-Emergent Serious Adverse Events. Planned start Sep 2023; status: authorised.
02
Drugs
amlitelimab
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on 2022-502188-39-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502188-39-00.